New Avenues in the Regulation of Gallbladder Motility—Implications for the Use of Glucagon-Like Peptide–Derived Drugs | Zendy

Ida M. Gether | Zendy; Christiexøe-Larsen | Zendy; Filip K. Knop | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

New Avenues in the Regulation of Gallbladder Motility—Implications for the Use of Glucagon-Like Peptide–Derived Drugs

Author(s) -

Ida M. Gether,

Christiexøe-Larsen,

Filip K. Knop

Publication year - 2018

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2018-01008

Subject(s) - motility , gallbladder , glucagon like peptide 1 , glucagon , peptide , glucagon like peptide 2 , medicine , chemistry , endocrinology , microbiology and biotechnology , biology , biochemistry , hormone , diabetes mellitus , type 2 diabetes

Several cases of cholelithiasis and cholecystitis have been reported in patients treated with glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) and GLP-2 receptor agonists (GLP-2RAs), respectively. Thus, the effects of GLP-1 and GLP-2 on gallbladder motility have been investigated. We have provided an overview of the mechanisms regulating gallbladder motility and highlight novel findings on the effects of bile acids and glucagon-like peptides on gallbladder motility.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research